Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system.
about
Trospium chloride treatment of overactive bladderSerum anticholinergic activity and cerebral cholinergic dysfunction: an EEG study in frail elderly with and without delirium.Recent advances in management of bladder overactivity.Challenges in clinical applications of brain computer interfaces in individuals with spinal cord injury.Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder.Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers.Tolterodine extended-release for overactive bladder.Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinenceOxybutynin: an overview of the available formulationsA comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.Clinical pharmacology of old age syndromesBladder, bowel, and sexual dysfunction in Parkinson's diseaseUse of CNS medications and cognitive decline in the aged: a longitudinal population-based studyOxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review.Urinary Urgency Medications May Compromise Discrete rather than Global Cognitive Skills.Tolterodine for the treatment of overactive bladder: a review.Trospium chloride: an anticholinergic quaternary ammonium compound for the treatment of overactive bladder.Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes.Diagnosis and management of patients with overactive bladder syndrome and abnormal detrusor activity.Therapy Insight: bladder dysfunction associated with multiple sclerosis.The emergence of new drugs for overactive bladder.Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management.Trospium chloride: the European experience.Developments in pharmacological therapy for the overactive bladder.Overactive bladder syndrome in older people.Pharmacologic management of overactive bladder.Tolterodine for the treatment of overactive bladder.The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderlyPreserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin.Update on tolterodine extended-release for treatment of overactive bladderTolterodine extended release is well tolerated in older subjectsRationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects.Treatment of dementia with lewy bodiesTreatment of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelinesAntimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients.Urinary incontinence: pharmacotherapy options.Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events?Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder.Anticholinergics for overactive bladder therapy: central nervous system effects.Contemporary management of overactive bladder.
P2860
Q28308162-825365B9-C32A-46B0-8CA5-CFFBAF11E7B5Q33369568-480E22A6-02E3-461E-9816-4E06478129E2Q34167658-88B5FD18-D744-4B53-BF68-E44A55563F82Q34239264-1E09143C-8996-4AFB-A14D-FD21857D50F7Q34515443-158483AD-E90F-4423-9899-C285C6461F51Q34561743-00108D5E-D208-42C9-88D3-8DAB75D1703CQ34610640-34E1B6C3-2C37-4A6D-8B78-29D045153386Q35166683-A7693806-73FF-4CA4-8188-82C8A77DAF6AQ35166777-5FCF16F9-29C0-428D-8BD8-ED0EA683A550Q35183619-B7133032-6BD8-4D29-AFAE-4C8EAD4629D8Q35200049-C340F2BE-8337-42AF-8DB9-F1ADEBBD3328Q35209869-8DB563FC-677C-49FB-9D18-31A8B421AA61Q35580037-3B59A9D1-01EC-4447-9D25-8F21DF1B56B1Q35925548-B563826F-E5F9-461E-943E-4E0F9A1F9427Q36100621-FA0BC86C-B564-4A6B-9D62-D1833261CAAFQ36150735-3419B80C-B60A-4510-A58E-7E1082E8B88CQ36192782-E95149D6-568B-4B10-8A97-ACCACE535630Q36283014-3174C3F1-8139-4BC0-94D2-5966E0FAE47CQ36395035-FD6922E3-74FF-46A7-A448-DD2F2DA51686Q36395096-1BA57C88-CE0A-44A3-A39D-18875A3B2F40Q36407417-52008B09-AE29-4D9B-8AF9-C83F890A53BDQ36434541-FA70A8F6-F5F0-4C74-94C6-E4FB0D0F2EDBQ36521876-49513C74-71E8-42D9-94DB-8876B15BC3C3Q36566857-8342E7D0-E3A4-4F8A-B3F7-E474CCB5CFE2Q36779724-0A706512-72CD-4D4B-9288-20D0D7095126Q37017434-24067E73-9E49-4A67-89C2-43101477C845Q37142090-97ECDF24-DA8F-4CA3-AA4C-5FB027858A4EQ37199946-9BCF62D6-FDB0-4611-A3C1-4FD066EE8635Q37242704-684BDF85-C366-4C64-9A05-535E89A16872Q37283585-D2040FE4-FABE-4A3B-9D3B-848EEE43DBA5Q37332901-A570C470-6721-4347-8E4C-D07D6B3FDF4EQ37399563-E94AF807-3968-4A6B-B92E-0F3388E6093FQ37552865-755B5226-14AD-4145-91CA-140E7E165FA9Q37720749-1822B085-E1DA-4298-86D2-0C0BA7075E22Q37879017-D3AAD807-1A86-4934-BD1A-9D7AF2F6FB19Q37884579-B4BD85D9-7199-402A-808A-3FE9BA8A66ACQ37896119-5C8E43CC-4FAA-4BA3-8237-89D905A56AB1Q37914849-CC0DF6C8-0F86-4DCB-B964-96BEA1B3C317Q37954372-8ACED723-670C-4B19-9ADD-DD24FC26021AQ37982213-A30A6772-7200-4C42-AF94-CCB7989B2DFF
P2860
Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system.
@en
Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system.
@nl
type
label
Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system.
@en
Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system.
@nl
prefLabel
Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system.
@en
Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system.
@nl
P2093
P2860
P1476
Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system.
@en
P2093
A Todorova
B Vonderheid-Guth
P2860
P304
P356
10.1177/00912700122010528
P577
2001-06-01T00:00:00Z